{
    "company_name": "TELIX PHARMACEUTICALS LIMITED",
    "address": "55 Flemington Road, NORTH MELBOURNE, VIC, AUSTRALIA, 3051",
    "summary": "Development and commercialising molecularly targeted radiation products for the treatment of cancer.",
    "details": "Development and commercialising molecularly targeted radiation products for the treatment of cancer.",
    "website": "http://www.telixpharma.com",
    "stock_code": "TLX",
    "links": "['https://telixpharma.com', 'https://telixpharma.com', 'https://telixpharma.com/our-company/', 'https://telixpharma.com/our-company/', 'https://telixpharma.com/our-company/purpose-mission-values/', 'https://telixpharma.com/our-company/board-management/', 'https://telixpharma.com/our-company/our-technology/', 'https://telixpharma.com/our-company/sustainability/', 'https://telixpharma.com/our-portfolio/', 'https://telixpharma.com/our-portfolio/', 'https://telixpharma.com/our-portfolio/disease-areas/', 'https://telixpharma.com/our-portfolio/disease-areas/prostate-cancer/', 'https://telixpharma.com/our-portfolio/disease-areas/kidney-cancer/', 'https://telixpharma.com/our-portfolio/disease-areas/brain-cancer/', 'https://telixpharma.com/our-portfolio/disease-areas/bone-marrow-conditioning/', 'https://telixpharma.com/our-portfolio/clinical-trials/', 'https://telixpharma.com/our-portfolio/products/illuccix/', 'https://telixpharma.com/our-portfolio/pipeline/', 'https://telixpharma.com/our-portfolio/research-innovation/', 'https://telixpharma.com/investor-centre/', 'https://telixpharma.com/investor-centre/', 'https://telixpharma.com/investor-centre/financial-reports-presentations/', 'https://telixpharma.com/investor-centre/corporate-governance/', 'https://telixpharma.com/investor-centre/asx-announcements/', 'https://telixpharma.com/investor-centre/investor-resources/', 'https://telixpharma.com/news-views/', 'https://telixpharma.com/careers/', 'https://telixpharma.com/careers/', 'https://telixpharma.com/careers/find-a-job/', 'https://telixpharma.com/our-company/', 'https://telixpharma.com/our-portfolio/pipeline/', 'https://telixpharma.com/our-portfolio/products/illuccix/', 'https://telixpharma.com/careers/', 'https://telixpharma.com/news-views/', 'https://telixpharma.com/news-views/telix-completes-acquisition-of-isotherapeutics/', 'https://telixpharma.com/news-views/telix-completes-acquisition-of-isotherapeutics/', 'https://telixpharma.com/news-views/telix-gm-2024/', 'https://telixpharma.com/news-views/telix-to-present-phase-iii-prostact-global-study-tlx591-therapy-and-phase-ii-starburst-study-tlx250-cdx-indication-expansion-at-eau/', 'https://telixpharma.com/news-views/world-first-use-of-lightpoints-sensei-drop-in-gamma-probe-in-bladder-cancer-surgery-performed-in-spain/', 'https://twitter.com/TelixPharma', 'https://www.linkedin.com/company/telixpharma', 'https://www.facebook.com/TelixPharma', 'https://www.youtube.com/TelixPharma', 'https://telixpharma.com/our-company/', 'https://telixpharma.com/contact/', 'https://telixpharma.com/our-portfolio/', 'https://telixpharma.com/careers/', 'https://telixpharma.com/investor-centre/', 'https://telixpharma.com/news-views/', 'https://telixpharma.com/privacy-policy/', 'https://telixpharma.com/terms-of-use/', 'https://telixpharma.com/cookies-statement/', '', 'https://investorcentre.linkmarketservices.com.au', 'mailto:LMSComms@linkmarketservices.com.au']",
    "images": "https://telixpharma.com/wp-content/themes/telix-1.10.0/build/assets/images/telix-logo-dark.svg, https://telixpharma.com/wp-content/themes/telix-1.10.0/build/assets/images/telix-logo-dark.svg, https://telixpharma.com/wp-content/themes/telix-1.10.0/build/assets/images/header-style-1-mobile-frame.svg, https://telixpharma.com/wp-content/themes/telix-1.10.0/build/assets/images/header-style-1-desktop-frame.svg, https://telixpharma.com/wp-content/uploads/2022/10/iStock-1322800279.jpg, https://telixpharma.com/wp-content/uploads/2022/10/Screen-Shot-2022-10-13-at-9.43.10-pm.png, https://telixpharma.com/wp-content/uploads/2022/08/Card-Image-2.jpg, https://telixpharma.com/wp-content/uploads/2022/10/illuccix.jpg, https://telixpharma.com/wp-content/uploads/2022/08/Card-Image-1.jpg, https://telixpharma.com/wp-content/uploads/2024/04/ITG-4-1200x675.png, https://telixpharma.com/wp-content/themes/telix-1.10.0/build/assets/images/telix-logo.svg",
    "company_logo_link": "https://telixpharma.com/wp-content/themes/telix-1.10.0/build/assets/images/telix-logo.svg"
}